Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola

2 ARTICLES PUBLISHED IN JoVE

Neuroscience

Measuring Contralateral Silent Period Induced by Single-Pulse Transcranial Magnetic Stimulation to Investigate M1 Corticospinal Inhibition

Ingrid Rebello-Sanchez¹, Joao Parente¹, Kevin Pacheco-Barrios^1,2, Anna Marduy¹, Danielle Carolina Pimenta¹, Daniel Lima¹, Eric Slawka¹, Alejandra Cardenas-Rojas¹, Gleysson Rodrigues Rosa¹, Kamran Nazim³, Abhishek Datta^3,4, Felipe Fregni¹

¹Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, ²Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola, ³Research and Development, Soterix Medical, ⁴City College of New York

Contralateral silent period (cSP) assessment is a promising biomarker to index cortical excitability and treatment response. We demonstrate a protocol to assess cSP intended for studying M1 corticospinal inhibition of upper and lower limbs.

Neuroscience

Understanding the Effects of Non-Invasive Transauricular Vagus Nerve Stimulation on EEG and HRV

Anna Carolyna Gianlorenco^1,2, Kevin Pacheco-Barrios^1,3, Lucas Camargo¹, Elly Pichardo¹, Hyuk Choi^4,5, Jae-Jun Song^5,6, Felipe Fregni¹

¹Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, ²Physical Therapy Department, Federal University of Sao Carlos, ³Vicerrectorado de Investigación, Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola, ⁴Department of Medical Sciences, Graduate School of Medicine, Korea University, ⁵Neurive Co., Ltd., ⁶Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Medical Center

This protocol provides information on how to apply transcutaneous auricular vagus nerve stimulation (taVNS) in a clinical trial, including potential biomarkers such as EEG metrics and heart rate variability (HRV) to measure the effect of this treatment on the autonomic nervous system.